Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
4 min read
Nelarabine: Detailed Review of its Transformative R&D Success, Mechanism of Action, and Drug Target
9 November 2023
This article summarized the latest R&D progress of Nelarabine, the Mechanism of Action for Nelarabine, and the drug target R&D trends for Nelarabine.
Hot Spotlight
6 min read
Patent Analysis of Jiangsu Hengrui's PARP1 Inhibitor HRS-1167
8 November 2023
In late October, Hengrui and Merck agreed on a €1.4 billion transaction, with a first payment of €160 million. The deal mainly involves Hengrui's self-developed PARP1 inhibitor HRS-1167 and Claudin-18.2 ADC SHR-A1904.
Drug Insights
4 min read
Lotilaner Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
8 November 2023
This article summarized the latest R&D progress of Lotilaner, the mechanism of action for Lotilaner, and the drug target R&D trends for Lotilaner.
Latest Hotspot
3 min read
2023 SITC | Junshi Biosciences announced the latest clinical results of PD-1 inhibitor Toripalimab
8 November 2023
Recent trial findings of Junshi Biosciences' Toripalimab and Cetuximab combo for treating R/M-HNSCC were shared at the 38th annual SITC meeting in 2023.
Drug Insights
4 min read
Unleashing the Power of Mebeverine Hydrochloride: A Comprehensive Review on R&D Breakthroughs
8 November 2023
This article summarized the latest R&D progress of Mebeverine Hydrochloride, the mechanism of action for Mebeverine Hydrochloride, and the drug target R&D trends for Mebeverine Hydrochloride.
Valuable Targets
6 min read
Analysis on the Research Progress of D2 Receptor Agonist
8 November 2023
The D2 receptor is a type of dopamine receptor found in the human body. It plays a crucial role in various physiological and neurological processes.
Drug Insights
4 min read
A Comprehensive Review of Melarsoprol's R&D Innovations and Drug Target Mechanism
8 November 2023
This article summarized the latest R&D progress of Melarsoprol, the Mechanism of Action for Melarsoprol, and the drug target R&D trends for Melarsoprol.
Latest Hotspot
4 min read
2023 AAO | Innovent Biologics Announces Latest Clinical Data for Dual-Target Ophthalmic New Drugs IBI302 and IBI324
8 November 2023
Innovent Biologics reported two clinical research outcomes at the 2023 AAO annual meeting on Nov 6, 2023. These include the Phase 2 clinical data for IBI302, an anti-VEGF-anti-complement dual target drug for nAMD treatment, and Phase 1 clinical data for IBI324, an anti-VEGF-A/Ang-2 bispecific antibody for DME treatment.
Drug Insights
4 min read
Pharmaceutical Insights: Menotropins's R&D Progress and its Mechanism of Action on Drug Target
8 November 2023
This article summarized the latest R&D progress of Menotropins, the Mechanism of Action for Menotropins, and the drug target R&D trends for Menotropins.
Bio Sequence
2 min read
Biological Glossary | What is Linker?
8 November 2023
In biology, linkers refer to short amino acid sequences found in nature that separate multiple domains in a single protein.
Latest Hotspot
3 min read
The phase 2 clinical trial of Otsuka/Visterra's anti-APRIL monoclonal antibody, sibeprenlimab, for the treatment of IgA nephropathy is published in the NEJM
8 November 2023
Otsuka Pharmaceutical and Visterra recently reported that the full Phase II trial results for sibeprenlimab (VIS649), a treatment for IgA nephropathy, have been published in the NEJM.
Drug Insights
4 min read
Exploring Metadoxine's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
8 November 2023
This article summarized the latest R&D progress of Metadoxine, the Mechanism of Action for Metadoxine, and the drug target R&D trends for Metadoxine.